Post on 12-Jan-2016
description
Optogenetic Neurostimulation
Revolutionizing Outcomes for Refractory Psychiatric Disorders Team Bambara
More than 50 % of Parkinson’s patients cannot be effectively treated with
pharmaceuticals
•
Treatment resistant psychiatric disorders have a large patient
population
REFRACTORY PARKINSON’S AND
ESSENTIAL TREMOR: 5.5 MILLION
REFRACTORY DEPRESSION: 4 MIILLION
REFRACTORY EPILESPY: 1 MILLION
•
Electrical Neurostimulation Devices: a close analog
Large revenueHigh growth
Significant limitations
•Limited efficacy•Severe side effects
•
Optogenetic neurostimulation directly addresses these two main limitations
“With its high specificity, optogenetics offers higher
efficacy and fewer side effects… Neurosurgeons’
primary criteria for purchasing a device are
efficacy, side effects, and reimbursement.”
-Dr. Raag AiranNeurosurgeon at Johns
Hopkins University
Light-sensitive genesare extractedLight-sensitive genesare extracted
Genes are added to patient’s DNA
1. Algae
Fiber optic cable is implanted in the brainFiber optic cable is implanted in the brain
Turn genes on/off with lights
Control neuron activation
2. Gene therapy
3. Surgery
4. Device Mediated Brain Management
5. A Better Life
OptogeneticNeurostimulation
Business Model
Technology Licensing:
OTL
Technology Licensing:
OTL
Device Manufacturing, Distribution, and Sales:
Medtronic
Device Manufacturing, Distribution, and Sales:
Medtronic
Licensers:Biotech Companies
Licensers:Biotech Companies
Purchasing Decision:
Neurosurgeons
Purchasing Decision:
Neurosurgeons
Care Providers:Hospitals
Care Providers:Hospitals
Payers:Medicare/Medicaid
Private Insurance
Payers:Medicare/Medicaid
Private Insurance
End Users:Patients
End Users:Patients
IPIP
IP
$$$
$$$
Capital Equipment & Disposables
$$$
Care
$$$
Major Risks
Medicare/Medicaid Coverage
Gene Therapy•Safety•Regulatory approval•Market adoption
Gene Therapy•Safety•Regulatory approval•Market adoption
Capital
Efficacy in humans
“We don’t yet know how to control expression for optogenetics gene therapy or if it will be safe.”
-Dr. Polina AnikeevaStanford Optogenetics Researcher
Pivot: apply optogenetics to screening
of novel pharmaceuticals
“More than 10% of the pharmaceutical screening market is for neural drugs…
Patch clamp technology for neural screening is currently too unreliable.”
-Dr. Solow-CorderoManager of Stanford High-Throughput
Bioscience Center